Bio-Rad to License Globavir Biosciences Dengue Detection Assay | GenomeWeb

NEW YORK (GenomeWeb) – Globavir Biosciences announced today that Bio-Rad Laboratories will license its PCR-based detection technology and assay for dengue virus detection.

Globavir's PanGlob assay improves diagnostic sensitivity and efficacy across four dengue serotypes, and it displays enhanced specificity for dengue over related viruses, the firm said. Globavir has obtained rights to develop and commercialize a dengue diagnostic test platform developed at Stanford University. Its diagnostic kits have received CE-mark approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.